Condition (MeSH)
Ciliary Motility Disorders
ClinicalTrials.gov lists 80 trials for Ciliary Motility Disorders or a narrower condition beneath it. ReCode Therapeutics has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
79 of the 80 trials are tagged with Ciliary Motility Disorders itself; the rest are tagged with a narrower condition beneath it.
When did Ciliary Motility Disorders trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 6 |
| 2024 | 3 |
| 2023 | 7 |
| 2022 | 2 |
| 2021 | 10 |
| 2020 | 6 |
| 2019 | 8 |
| 2017 | 7 |
| 2016 | 6 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ciliary Motility Disorders trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Not applicable | 19 |
| Observational | 56 |
How many Ciliary Motility Disorders trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 17 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 3 |
| Completed | 37 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ciliary Motility Disorders trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| ReCode Therapeutics | 5 |
| Ziv Hospital | 3 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
Which drugs are being tested for Ciliary Motility Disorders? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Ivacaftor | 1 |
| Thiamine | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| RCT1100 | 3 |
| data collection | 1 |
| Physiotherapy | 1 |
| Salbutamol MDI | 1 |
| VX-371 + HS | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Ciliary Motility Disorders trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Lung disorder | 2 | 1 |
| Bronchiectasis | 1 | 1 |
| Haemoptysis | 1 | 1 |
| Pneumonia | 1 | 1 |
Which publications cover Ciliary Motility Disorders? (65)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial. | The Lancet. Respiratory medicine | 2024 | Yes |
| Airway Inflammation in Children with Primary Ciliary Dyskinesia. | Annals of the American Thoracic Society | 2023 | Yes |
| Aerobic exercise capacity, cough strength, posture, and depression in primary ciliary dyskinesia. | Pediatric pulmonology | 2023 | Yes |
| Nasal nitric oxide measurement in children for the diagnosis of primary ciliary dyskinesia: European Respiratory Society technical standard. | The European respiratory journal | 2023 | Yes |
| Respiratory muscle strength, exercise capacity and physical activity in patients with primary ciliary dyskinesia: A cross-sectional study. | Respiratory medicine | 2022 | Yes |
Showing 5 of 65 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Primary ciliary dyskinesia | Point prevalence | 1-5 / 10 000 | Pakistan | Not stated | Unspecified |
| Primary ciliary dyskinesia | Prevalence at birth | 1-9 / 100 000 | Europe | Not stated | Unspecified |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity.